What is Aitia?
Aitia operates as a leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning, the company reveals hidden biological mechanisms of disease. Its Gemini Digital Twins are currently deployed to accelerate research in oncology, neurodegenerative disorders, and immunology, including Alzheimer's and Parkinson's disease. With a client roster that includes seven of the top ten pharmaceutical companies, Aitia is effectively bridging the gap between complex biological data and actionable therapeutic insights.
How much funding has Aitia raised?
Aitia has raised a total of $69.6M across 10 funding rounds:
Series B
$9.9M
Multiple Rounds
$18.9M
Private Equity
$4M
Private Equity
$6M
Series D
$23M
Debt
$1M
Debt
$1.8M
Series B (2013): $9.9M led by Heritage Provider Network, Cambia Health Solutions, and Mitsui & Co, Ltd.
Debt (2015): $750K, investors not publicly disclosed
Private Equity (2015): $8.1M, investors not publicly disclosed
Series C (2015): $10M backed by Celgene Corporation, Alexandria Real Estate Equities, and Cambia Health Solutions
Private Equity (2016): $4M with participation from Echo Health Ventures
Private Equity (2017): $6M led by Alexandria Real Estate Equities
Series D (2019): $23M, investors not publicly disclosed
Debt (2020): $1M featuring PPP
Debt (2021): $1.8M backed by PPP
Key Investors in Aitia
Celgene Corporation
A global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and inflammatory diseases.
Alexandria Real Estate Equities
An urban office real estate investment trust uniquely focused on collaborative science and technology campuses in key innovation clusters.
Cambia Health Solutions
A health solutions company dedicated to transforming the health care system through innovative investments and consumer-focused services.
What's next for Aitia?
With the support of its latest capital injection, Aitia is poised to scale its Gemini Digital Twin platform across a broader spectrum of therapeutic areas. The strategic focus remains on deepening partnerships with academic research centers and medical societies to refine its causal learning models. As the firm continues to integrate multi-omic datasets, it is well-positioned to shorten the drug discovery lifecycle, potentially transforming the economics of pharmaceutical development and establishing a new standard for precision medicine in the global market.
See full Aitia company page
